Biogen (BIIB) Price Target Raised to $325 at RBC Capital
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


